ClinicalTrials.gg

Program

garetosmab

Also written as “Garetosmab”, “REGN2477” and “REGN2477+REGN1033”.

Its studies are mostly in Myositis Ossificans · Obesity · Ossification, Heterotopic · Myositis, Inclusion Body, led by Regeneron Pharmaceuticals.

Furthest: phase 3, since Sep 30, 20209 company-led studies, 2 open or runningNext primary completion: Jul 8, 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals92 open or runningphase 3since Sep 30, 2020Aug 12, 2016Jul 8, 2030phase 3 · NCT07559513

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 12, 2016First study: phase 1 study in Healthy VolunteersFirst studyNCT02870400 · 41 enrolled · Belgium
  2. Oct 19, 2016Phase 1 study in Healthy VolunteersNCT02943239 · 82 enrolled · New Zealand
  3. Jun 13, 2017Phase 2 study in Myositis OssificansNCT03188666 · 44 enrolled · United States, Canada, France and more
  4. Oct 15, 2018Phase 2 study in Myositis, Inclusion BodyNCT03710941
  5. Sep 30, 2020Phase 3 study in Ossification, HeterotopicNCT04577820
  6. May 4, 2022Phase 3 study in Myositis OssificansNCT05394116 · 63 enrolled · United States, Australia, Brazil and more
  7. Mar 1, 2024Phase 2 study in ObesityNCT06299098 · 1,005 enrolled · United States, Puerto Rico
  8. May 6, 2025Phase 1 study in ObesityNCT06970405
  9. Apr 22, 2026Phase 3 study in Myositis OssificansNCT07559513 · 18 planned
  10. Oct 8, 2026Primary completion moved from 2028-12-10 to 2030-07-08Date moved laterphase 3 · +19 months · NCT07559513

Ahead

  1. Jul 8, 2030Primary completion: phase 3 study in Myositis OssificansNCT07559513

TargetBeta

INHBA →read by rule
“Inhibin beta A chain inhibitor”ChEMBL 37, by rule

Other programs on INHBA

ProgramCompanyFurthest phaseStudies
sotaterceptruleMerckphase 426

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07559513Myositis Ossificans3Not yet recruitingJul 8, 203018
NCT06970405Obesity1WithdrawnJun 8, 20260
NCT06299098Obesity · United States, Puerto Rico2CompletedJun 16, 20261,005
NCT05394116Myositis Ossificans · United States, Australia, Brazil and more3Active, not recruitingJul 17, 202563
NCT04577820Ossification, Heterotopic3WithdrawnMar 1, 20220
NCT03710941Myositis, Inclusion Body2WithdrawnAug 27, 20200
NCT03188666Myositis Ossificans · United States, Canada, France and more2CompletedSep 16, 201944
NCT02943239Healthy Volunteers · New Zealand1CompletedApr 30, 201982
NCT02870400Healthy Volunteers · Belgium1CompletedJan 12, 201741

How it is read

Names in the registry

  • “Garetosmab”, 3 entries
  • “REGN2477”, 3 entries
  • “garetosmab”, 2 entries
  • “REGN2477+REGN1033”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.